Mylan Announces Pricing of Senior Notes

                   Mylan Announces Pricing of Senior Notes

PR Newswire

PITTSBURGH, Dec. 12, 2012

PITTSBURGH, Dec. 12, 2012 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced the pricing of a private placement of $750 million aggregate
principal amount of 3.125% Senior Notes due 2023 at an issue price of 99.793%.
Mylan intends to use the net proceeds from the offering to repay amounts
borrowed under its revolving credit facility and accounts receivable
securitization facility, including borrowings used or to be used to support
the previously announced repurchase of up to $500 million of its common stock
in the open market and through other methods, and for general corporate
purposes. Subject to customary closing conditions, the sale of the notes is
expected to close on or about Dec. 21, 2012.

The notes will be sold only to qualified institutional buyers inthe United
Statesin reliance on Rule144A under the Securities Act of 1933, and outside
the United Statesto non-U.S. persons in reliance on RegulationS under the
Securities Act. The proposed issuance of the notes will not be registered
under the Securities Act, and may not be offered or sold inthe United
Statesabsent registration or an applicable exemption from registration
requirements. This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any securities, nor shall there be any sale
of securities mentioned in this press release in any state in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active pharmaceutical
ingredient manufacturers and currently market products in approximately 150
countries and territories. Our workforce of more than 18,000 people is
dedicated to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for it. See for
yourself. See

This press release includes statements that constitute "forward-looking
statements." These statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Because such
statements inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such differences
include, but are not limited to, Mylan's failure to consummate the private
placement or to utilize the proceeds of such placement as described in this
press release. These cautionary statements should be considered in connection
with any subsequent written or oral forward-looking statements that may be
made by Mylan or by persons acting on its behalf and in conjunction with its
periodic SEC filings. In addition, please refer to the cautionary statements
and risk factors set forth in Mylan's Quarterly Report on Form 10-Q for the
period ended September 30, 2012 and in its other periodic filings made with
the SEC from time to time.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), +1-724-514-1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.